A Phase 1 interventional study of Placebo and Abatacept in Lupus Nephritis, sponsored by Bristol-Myers Squibb. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-30.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.
Among the 96 studies in Lupus Nephritis with a site in China, this one is the 80th largest by enrollment of the 88 interventional ones that give a count, is one of 2 that started in 2008, is one of 15 in phase 1, and was the 11th registered.
343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.
Browse Lupus Nephritis studies →43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 6–18
Beijing GoBroad Hospital · Sites in China
Ages 6–65
Beijing Biotech · Sites in China
Ages 18–70
Nanjing University School of Medicine · Sites in China
Ages 14–65
China Immunotech (Beijing) Biotechnology Co., Ltd. · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 31 · Phase 3 22 · Phase 4 7
First in 1996; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 48 across 242 interventional studies indexed under Lupus Nephritis.
Median enrollment 51 across the 88 interventional studies, 400 across the 7 observational. Of the 34 that completed or were terminated, 11 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 96 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 6 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
17 of the studies in Lupus Nephritis with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT06406205Phase 3Qilu Pharmaceutical Co., Ltd.A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis | 2027-06 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT07236762China Immunotech (Beijing) Biotechnology Co., Ltd.An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | 2026-11-24 |
| NCT07706998Nanjing UniversityApplication of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 96 studies in Lupus Nephritis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus (SLE)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Abatacept
Open-label long-term extension phase
Drug: Abatacept
Infusion, Intravenous, single dose, Day 1
Infusion, Intravenous, 30mg/kg, single dose, Day 1
Also known as: Orencia, BMS-188667
Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
Also known as: Orencia, BMS-188667
Short-term Period: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, Discontinuations and Infusional AEs
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
Time frame: From Day 1 of double-blind period to 1st dose of long-term period
Short-term Period: Number of Adverse Events (AEs) Related to Study Drug
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. Intensity = mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening/disabling (grade 4).
Time frame: From Day 1 of double-blind period to 1st dose of long-term period
Short-term Period: MeanSystolic and Diastolic Blood Pressure
Vital sign measurements are summarized without regard to position (sitting, standing, supine).
Time frame: Day 1 predose and postdose and Day 2
Short-term Period: Mean Heart Rate
Vital signs measurements are summarized without regard to position (sitting, standing, supine).
Time frame: Day 1 predose and postdose and Day 2
Short-term Period: Mean Respirations Rate
Vital sign measurements are summarized without regard to position (sitting, standing, supine).
Time frame: Day 1 predose and postdose and Day 2
Short-term Period: Mean Temperature
Vital sign measurements are summarized without regard to position (sitting, standing, supine).
Time frame: Day 1 predose and postdose and Day 2
Short-term Period: Number of Participants With Clinical Laboratory and Electrocardiogram (ECG) Abnormalities
Laboratory tests consisted of complete blood count, chemistry, and urinalysis.
Time frame: Screening and Days 1 and 2
Long-term Period: Number of Participants With Death as Outcome, Serious AEs (SAEs), Discontinuations Due to AEs, and Treatment-related AEs
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
Time frame: Days 15 to 56 days post last dose of the long-term period
Minimum (Cmin) Plasma Concentration of Abatacept
Cmin is the minimum, or trough, concentration of a drug observed after its administration and just prior to the administration of a subsequent dose.
Time frame: Days 15, 29, 85, 169, 253 and 337
Maximum (Cmax) Plasma Concentration of Abatacept
Cmax is a drug's maximum, or peak, concentration observed after its administration.
Time frame: Postdosing Day 1
Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. hemoglobin (g/dL): \>3g/dL drop from preRX; hematocrit (%): \<0.75\*preRX; erythrocytes (\*10\^6 c/uL): \<0.75\*preRX; platelet count (\*10\^9 c/L): \<0.67\*LLN or \>1.5\*ULN, or \<100,000/mm\^3 or if preRX\<LLN, use \<0.5\*preRX and \<100,000/mm\^3; leukocytes (\*10\^3 c/uL): \<0.75\*LLN, \>1.25\*ULN, \<0.8\*preRX if preRX \<LLN or \>1.2\*preRX if preRX \>ULN; \>ULN if preRX \<LLN, \<LLN if \>ULN preRX; neutrophils+bands (\*10\^3 c/uL): if value \<1.00\*10\^3 c/uL; lymphocytes (\*10\^3 c/uL): if value \<0.750\*10\^3 c/uL or if value \>7.50\*10\^3 c/uL; monocytes (\*10\^3 c/uL): if value \>2000/mm\^3; basophils (\*10\^3 c/uL): if value \>400/mm\^3; eosinophils (\*10\^3 c/uL): if value\> 0.750\*10\^3 c/uL
Time frame: Days 15 to 56 days post last dose of the long-term period
Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Glucose (mg/dL): \<65 or \>220. Glucose, fasting(mg/dL): \<0.8\*LLN or \>1.5\* ULN; if preRX\<LLN, use \<0.8\*preRX or \>ULN; if preRX\>ULN, use \>2.0\*preRX or \<LLN. Protein, total (g/dL): \<0.9\*LLN or \>1.1\*ULN; if preRX\<LLN, use 0.9\*preRX or \>ULN if preRX \>ULN, use 1.1\*preRX or \<LLN. Albumin (g/dL): \<0.9\*LLN, or if preRX\<LLN use \<0.75\*preRX. Uric acid (mg/dL): \>1.5\*ULN; if preRX\>ULN use \>2\*preRX. Protein, urine: if missing preRX, use\>=2; if \>=4; if preRX=0 or 0.5, use \>=2; if preRX=1, use \>=3, or if preRX=2 or 3, use \>= 4. Glucose, urine: if preRX missing, use \>=2; if \>=4, or if preRX=0 or 0.5 use \>=2,or if preRX=1, use \>=3, or if preRX=2 or 3 use \>=4. Blood, urine: if preRX missing, use\>= 2, or if \>=4, or if preRX=0 or 0.5, use \>=2, or if preRX=1, use \>=3; if preRX=2 or 3 use \>=4. WBC, urine (hpf): if missing preRX, use\>= 2, or if \>= 4, or if preRX =0 or 0.5 use \>=2, or if preRX=1 use \>=3, or if preRX=2 or 3 use \>=4.
Time frame: Days 15 to 56 days post last dose of the long-term period
Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)
ULN=upper limit of normal; preRX=pretreatment: ALP (U/L): \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; AST (U/L): \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALT (U/L): \>3X\*ULN, or if preRX\>ULN, use \>4\*preRX; GGT (/L): \>\*ULN, or if preRX\>ULN, use \>3\*preRX; bilirubin (mg/dL): \>2\*ULN, or if preRX\>ULN, use \>4\*preRX; BUN (mg/dL):\>2\*preRX; sodium: \<.95\*LLN, \>1.05\*ULN, \<.95\* preRX if \<LLN preRX, \>1.05\*preRX if \>ULN preRX; \>ULN if \<LLN preRX, \<LLN if \>ULN preRX; potassium: chloride: calcium: phosphorous:
Time frame: Days 15 to 56 days post last dose of the long-term period
Long-term Period: Number of Participants With Abatacept-specific Antibodies
Antiabatacept antibodies in human serum were assayed using a validated electrochemiluminescent immunoassay during the period of known analyte stability.
Time frame: Day15 to 56 days post last dose of the long-term period
| Milestone | Abatacept, 30/10 mg/kg | Placebo/Abatacept,10 mg/kg |
|---|---|---|
| Started | 6 | 3 |
| Completed | 6 | 3 |
| Not completed | 0 | 0 |
| Milestone | Abatacept, 30/10 mg/kg | Placebo/Abatacept,10 mg/kg |
|---|---|---|
| Started | 9 | 0 |
| Completed | 0 | 0 |
| Not completed | 9 | 0 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: No longer met study criteria | 1 | 0 |
| Withdrew: Administrative reason by sponsor | 3 | 0 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
| Participants | Abatacept (30 mg/kg) | Placebo |
|---|---|---|
| Deaths | 0 | 0 |
| SAEs | 0 | 0 |
| AEs | 3 | 1 |
| Discontinued due to AEs | 0 | 0 |
| Acute infusional AEs | 0 | 0 |
| Peri-infusional AEs | 0 | 0 |
AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.
| Participants | Abatacept (10 mg/kg) |
|---|---|
| Deaths | 0 |
| SAEs | 0 |
| Discontinuations due to AEs | 2 |
| AEs | 8 |
| Treatment-related AEs | 6 |
Cmin is the minimum, or trough, concentration of a drug observed after its administration and just prior to the administration of a subsequent dose.
| ug/mL | Abatacept (10 mg/kg) |
|---|---|
| Day 15 (n=6) | 55.47 ± 29.356 |
| Day 29 (N=9) | 42.69 ± 12.534 |
| Day 85 (n=8) | 18.54 ± 11.492 |
| Day 169 (n=7) | 22.66 ± 10.312 |
| Day 253 (n=7) | 28.24 ± 13.883 |
| Day 337 (n=4) | 25.98 ± 6.833 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. Intensity = mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening/disabling (grade 4).
| Events | Abatacept (30 mg/kg) | Placebo |
|---|---|---|
| Dizziness (mild) | 1 | 0 |
| Oropharyngeal pain (mild) | 1 | 0 |
| Diarrhea (mild) | 0 | 1 |
Vital sign measurements are summarized without regard to position (sitting, standing, supine).
| mm Hg | Abatacept (30 mg/kg) | Placebo |
|---|---|---|
| Systolic blood pressure: Day 1 predose | 129.0 ± 20.47 | 133.0 ± 8.89 |
| Systolic blood pressure: Day 1 postdose | 125.8 ± 19.58 | 131.7 ± 9.29 |
| Diastolic blood pressure: Day 1 predose | 84.2 ± 8.86 | 78.3 ± 12.06 |
| Diastolic blood pressure: Day 1 postdose | 82.7 ± 9.58 | 82.7 ± 14.22 |
| Systolic blood pressure: Day 2 | 127.5 ± 13.69 | 126.7 ± 11.55 |
| Diastolic blood pressure: Day 2 | 79.5 ± 8.69 | 78.3 ± 10.41 |
Vital signs measurements are summarized without regard to position (sitting, standing, supine).
| beats per minute | Abatacept (30 mg/kg) | Placebo |
|---|---|---|
| Day 1 predose | 77.0 ± 8.49 | 81.0 ± 10.15 |
| Day 1 postdose | 81.2 ± 4.83 | 87.7 ± 19.60 |
| Day 2 | 83.5 ± 4.46 | 84.0 ± 5.29 |
Vital sign measurements are summarized without regard to position (sitting, standing, supine).
| Respirations per minute | Abatacept (30 mg/kg) | Placebo |
|---|---|---|
| Day 1 predose | 17.7 ± 2.07 | 19.7 ± 2.08 |
| Day 1 postdose | 18.7 ± 1.63 | 20.3 ± 2.52 |
| Day 2 | 14.0 ± 3.35 | 17.3 ± 1.15 |
Cmax is a drug's maximum, or peak, concentration observed after its administration.
| ug/mL | Abatacept (10 mg/kg) |
|---|---|
| Maximum (Cmax) Plasma Concentration of Abatacept | 463.10 ± 17 |
Vital sign measurements are summarized without regard to position (sitting, standing, supine).
| Degrees Celsius | Abatacept (30 mg/kg) | Placebo |
|---|---|---|
| Day 1 predose | 36.7 ± 0.51 | 36.7 ± 0.15 |
| Day 1 postdose | 36.8 ± 0.59 | 36.9 ± 0.26 |
| Day 2 | 36.9 ± 0.11 | 36.9 ± 0.12 |
Laboratory tests consisted of complete blood count, chemistry, and urinalysis.
| Participants | Abatacept (30 mg/kg) | Placebo |
|---|---|---|
| Laboratory Abnormalities | 0 | 0 |
| ECG Abnormalities | 0 | 0 |
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. hemoglobin (g/dL): \>3g/dL drop from preRX; hematocrit (%): \<0.75\*preRX; erythrocytes (\*10\^6 c/uL): \<0.75\*preRX; platelet count (\*10\^9 c/L): \<0.67\*LLN or \>1.5\*ULN, or \<100,000/mm\^3 or if preRX\<LLN, use \<0.5\*preRX and \<100,000/mm\^3; leukocytes (\*10\^3 c/uL): \<0.75\*LLN, \>1.25\*ULN, \<0.8\*preRX if preRX \<LLN or \>1.2\*preRX if preRX \>ULN; \>ULN if preRX \<LLN, \<LLN if \>ULN preRX; neutrophils+bands (\*10\^3 c/uL): if value \<1.00\*10\^3 c/uL; lymphocytes (\*10\^3 c/uL): if value \<0.750\*10\^3 c/uL or if value \>7.50\*10\^3 c/uL; monocytes (\*10\^3 c/uL): if value \>2000/mm\^3; basophils (\*10\^3 c/uL): if value \>400/mm\^3; eosinophils (\*10\^3 c/uL): if value\> 0.750\*10\^3 c/uL
| Participants | Abatacept, 30/10 mg/kg |
|---|---|
| Hemoglobin (low) | 1 |
| Hemoglobin (high) | NA |
| Hematocrit (low) | 1 |
| Hematocrit (high) | NA |
| Erythrocytes (low) | 0 |
| Erythrocytes (high) | NA |
| Platelet count (low or high) | 0 |
| Leukocytes (low) | 1 |
| Leukocytes (high) | 0 |
| Neutrophils +bands (absolute) (low) | NA |
| Neutrophils +bands (absolute) (high) | 0 |
| Absolute lymphocytes (low) | 6 |
| Absolute lymphocytes (high) | 0 |
| Absolute monocytes (low) | NA |
| Absolute monocytes (high) | 0 |
| Absolute basophils (low) | NA |
| Absolute basophils (high) | 0 |
| Absolute eosinophils (low) | NA |
| Absolute eosinophils (high) | 0 |
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Glucose (mg/dL): \<65 or \>220. Glucose, fasting(mg/dL): \<0.8\*LLN or \>1.5\* ULN; if preRX\<LLN, use \<0.8\*preRX or \>ULN; if preRX\>ULN, use \>2.0\*preRX or \<LLN. Protein, total (g/dL): \<0.9\*LLN or \>1.1\*ULN; if preRX\<LLN, use 0.9\*preRX or \>ULN if preRX \>ULN, use 1.1\*preRX or \<LLN. Albumin (g/dL): \<0.9\*LLN, or if preRX\<LLN use \<0.75\*preRX. Uric acid (mg/dL): \>1.5\*ULN; if preRX\>ULN use \>2\*preRX. Protein, urine: if missing preRX, use\>=2; if \>=4; if preRX=0 or 0.5, use \>=2; if preRX=1, use \>=3, or if preRX=2 or 3, use \>= 4. Glucose, urine: if preRX missing, use \>=2; if \>=4, or if preRX=0 or 0.5 use \>=2,or if preRX=1, use \>=3, or if preRX=2 or 3 use \>=4. Blood, urine: if preRX missing, use\>= 2, or if \>=4, or if preRX=0 or 0.5, use \>=2, or if preRX=1, use \>=3; if preRX=2 or 3 use \>=4. WBC, urine (hpf): if missing preRX, use\>= 2, or if \>= 4, or if preRX =0 or 0.5 use \>=2, or if preRX=1 use \>=3, or if preRX=2 or 3 use \>=4.
| Participants | Abatacept, 30/10 mg/kg |
|---|---|
| Glucose, serum (low) | 2 |
| Glucose, serum (high) | 0 |
| Glucose, fasting serum (low) | 0 |
| Glucose, fasting serum (high) | 0 |
| Protein, total (low) | 0 |
| Protein, total (high) | 0 |
| Albumin (low) | 0 |
| Albumin (high) | NA |
| Uric acid (low) | NA |
| Uric acid (high) | 0 |
| Protein, urine (low) | NA |
| Protein, urine (high) | 1 |
| Glucose, urine (low) | NA |
| Glucose, urine (high) | 0 |
| Blood, urine (low) | NA |
| Blood, urine (high) | 5 |
| WBC, urine (low) | NA |
| White blood cell (WBC) count, urine (high) | 3 |
ULN=upper limit of normal; preRX=pretreatment: ALP (U/L): \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; AST (U/L): \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALT (U/L): \>3X\*ULN, or if preRX\>ULN, use \>4\*preRX; GGT (/L): \>\*ULN, or if preRX\>ULN, use \>3\*preRX; bilirubin (mg/dL): \>2\*ULN, or if preRX\>ULN, use \>4\*preRX; BUN (mg/dL):\>2\*preRX; sodium: \<.95\*LLN, \>1.05\*ULN, \<.95\* preRX if \<LLN preRX, \>1.05\*preRX if \>ULN preRX; \>ULN if \<LLN preRX, \<LLN if \>ULN preRX; potassium: chloride: calcium: phosphorous:
| Participants | Abatacept, 30/10 mg/kg |
|---|---|
| Alkaline phosphatase (ALP) (low) | NA |
| ALP (high) | 0 |
| Aspartate aminotransferase (AST) (low) | NA |
| AST (high) | 0 |
| Alanine aminotransferase (ALT) (low) | NA |
| ALT (high) | 0 |
| G-glutamyl transferase (GGT) (low) | NA |
| GGT (high) | 0 |
| Bilirubin, total (low) | NA |
| Bilirubin, total (high) | 0 |
| Blood urea nitrogen (BUN) (low) | NA |
| BUN (high) | 0 |
| Sodium, serum (low) | 0 |
| Sodium, serum (high) | 1 |
| Potassium, serum (low) | 0 |
| Potassium, serum (high) | 0 |
| Chloride, serum (low) | 0 |
| Chloride, serum (high) | 0 |
| Calcium, total (low) | 0 |
| Calcium, total (high) | 0 |
| Phosphorus, inorganic (low) | 0 |
| Phosphorus, inorganic (high) | 2 |
Antiabatacept antibodies in human serum were assayed using a validated electrochemiluminescent immunoassay during the period of known analyte stability.
| Participants | Abatacept (10 mg/kg) |
|---|---|
| Long-term Period: Number of Participants With Abatacept-specific Antibodies | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept 30 mg/kg | — | 0/6 (0%) | 3/6 (50%) |
| Placebo | — | 0/3 (0%) | 1/3 (33.3%) |
| Event | Abatacept 30 mg/kg | Placebo |
|---|---|---|
| DIARRHOEAGastrointestinal disorders | 1/6 | 1/3 |
| DIZZINESSNervous system disorders | 1/6 | 0/3 |
| VOMITINGGastrointestinal disorders | 1/6 | 0/3 |
| ABDOMINAL PAINGastrointestinal disorders | 1/6 | 0/3 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 1/6 | 0/3 |
| Age Continuous(years) | Abatacept (30 mg/kg) | Placebo | Total |
|---|---|---|---|
| Mean | 32.50 ± 8.76 | 41.33 ± 8.33 | 35.44 ± 9.21 |
| Sex: Female, Male(Participants) | Abatacept (30 mg/kg) | Placebo | Total |
|---|---|---|---|
| Female | 6 | 2 | 8 |
| Male | 0 | 1 | 1 |
| Region of Enrollment(participants) | Abatacept (30 mg/kg) | Placebo | Total |
|---|---|---|---|
| China | 6 | 3 | 9 |
| Duration of Lupus Nephritis(months) | Abatacept (30 mg/kg) | Placebo | Total |
|---|---|---|---|
| Mean | 41.23 ± 32.90 | 85.26 ± 65.03 | 55.90 ± 47.10 |
| Duration of Systemic Lupus Erythematosus (SLE)(years) | Abatacept (30 mg/kg) | Placebo | Total |
|---|---|---|---|
| Mean | 7.20 ± 5.06 | 11.11 ± 3.18 | 8.50 ± 4.73 |
| Weight(kg) | Abatacept (30 mg/kg) | Placebo | Total |
|---|---|---|---|
| Mean | 58.83 ± 10.38 | 63.67 ± 4.04 | 60.44 ± 8.79 |
The record gives a start of Aug 2008, a primary completion of Jan 2009 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept